Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AURORA phase 3 trial of cenicriviroc for liver fibrosis in adults with nonalcoholic steatohepatitis
MOH_2017-10-16_000156Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) and hepatic fibrosis comparing Cenicriviroc 150 mg with Placebo (2 arms). Started Mar 2017; status: recruiting.
02
Drugs
cenicriviroc
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)hepatic fibrosis
Beyond the preview
Go deeper on MOH_2017-10-16_000156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-10-16_000156.